A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD

In brief

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects with F2 or F3 fibrosis (NASH CRN system). Antifibrotic biomarker activity will be evaluated on an exploratory basis.

Key facts

Study ID
NCT05402371
Run by
Hepion Pharmaceuticals, Inc.
People needed
120
Starts
2022-10-15
Expected to finish
2025-09-01
Last updated by the study team
2024-05-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.